| 14.27 -0.39 (-2.66%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 25.6  |
1-year : | 31.18 |
| Resists | First : | 21.92 |
Second : | 26.7 |
| Pivot price | 18.3 |
|||
| Supports | First : | 14.19 |
Second : | 11.81 |
| MAs | MA(5) : | 15.37 |
MA(20) : | 19.49 |
| MA(100) : | 17.52  |
MA(250) : | 11.25 |
|
| MACD | MACD : | -2.1 |
Signal : | -1.5 |
| %K %D | K(14,3) : | 1.4 |
D(3) : | 1.3 |
| RSI | RSI(14): 22.1 |
|||
| 52-week | High : | 30.95 | Low : | 4.44 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ IMNM ] has closed above bottom band by 6.7%. Bollinger Bands are 54.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 15.02 - 15.16 | 15.16 - 15.25 |
| Low: | 13.9 - 14.08 | 14.08 - 14.2 |
| Close: | 14.06 - 14.36 | 14.36 - 14.54 |
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Wed, 24 Apr 2024
Cerity Partners LLC Acquires New Position in Immunome, Inc. (NASDAQ:IMNM) - MarketBeat
Mon, 22 Apr 2024
Immunome (NASDAQ:IMNM) Shares Gap Up to $15.48 - MarketBeat
Thu, 04 Apr 2024
Insider Stock Buying Of Immunome Delivers Return On US$1.25m Investment - Simply Wall St
Tue, 02 Apr 2024
Immunome: An Oncology Powerhouse In The Making (NASDAQ:IMNM) - Seeking Alpha
Thu, 28 Mar 2024
Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets - Business Wire
Fri, 22 Mar 2024
Immunome, Inc. (NASDAQ:IMNM) surges 7.6%; individual investors who own 42% shares profited along with institutions - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 60 (M) |
| Shares Float | 44 (M) |
| Held by Insiders | 18.1 (%) |
| Held by Institutions | 37.5 (%) |
| Shares Short | 3,240 (K) |
| Shares Short P.Month | 2,650 (K) |
| EPS | -5.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.76 |
| Profit Margin | 0 % |
| Operating Margin | -362.1 % |
| Return on Assets (ttm) | -20.9 % |
| Return on Equity (ttm) | -156.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.23 |
| EBITDA (p.s.) | -0.48 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -8 (M) |
| Levered Free Cash Flow | 2 (M) |
| PE Ratio | -2.66 |
| PEG Ratio | 0 |
| Price to Book value | 5.15 |
| Price to Sales | 60.75 |
| Price to Cash Flow | -112.52 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|